AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT05081089
Drug: Artemether-lumefantrine
RxNorm normalized name: artemether-lumefantrine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tablets containing 20/80 mg artemether and 120/480 mg lumefantrine will be administered according to weight as per manufacturer guidelines.
Trial: NCT05305625
Drug: standard therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: received standardized treatment
Trial: NCT04930900
Drug: ARS-1 with URTI
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ARS-1
Trial: NCT04930900
Drug: ARS-1 without URTI
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ARS-1 without URTI
Trial: NCT05179057
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered as 2-4 milliliter infusion, visually identical to Posoleucel
Trial: NCT00085345
Drug: ascorbic acid
RxNorm normalized name: Ascorbic Acid
DrugBank: Ascorbic acid (DB00126)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT06480123
Drug: Skin drug prepared with exome originated from stem cell
RxNorm normalized name: human skin preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Skin drug prepared with exome originated from stem cell will be applied to patient with diabetic foot.
Trial: NCT05282771
Drug: Duobrii® Lotion (Halobetasol propionate and tazarotene lotion), 0.01%/0.045%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The study drug is to be self-administered by applying as a thin layer once daily to cover only affected areas and rubbed in gently for approximately 8 weeks.
Trial: NCT05282771
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The study drug is to be self-administered by applying as a thin layer once daily to cover only affected areas and rubbed in gently for approximately 8 weeks.
Trial: NCT06009198
Drug: Iron folate tablets
RxNorm normalized name: folate
DrugBank: Folic acid (DB00158)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Iron folate tablets will be administered to the underweight school going adolescents girls and boys to see the affect on BMI and micronutrients
Trial: NCT05357027
Drug: Cyclophosphamide Capsules
RxNorm normalized name: Cyclophosphamide Capsules
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Part of the non-myeloablative lymphocyte-depleting preparative regimen.
Trial: NCT06010342
Drug: TL118 Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral administration
Trial: NCT05427175
Drug: Methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Patients will receive 25 mg/1ml of methotrexate vial per week for 3 successive months
Trial: NCT04800224
Drug: Standardized Brazilian Green Propolis Extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 900mg/day of Standardized Brazilian Green Propolis Extract for 10 days.
Trial: NCT04800224
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 900mg/day of Placebo for 10 days.
Trial: NCT04303559
Drug: Eloctate Injectable Product
RxNorm normalized name: Eloctate Injectable Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: This is a factor VIII-Fc fusion protein.
Trial: NCT03720990
Drug: Cholic Acid
RxNorm normalized name: Cholic Acid
DrugBank: Cholic Acid (DB02659)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Participants will be treated with cholic acid for 8 weeks
Trial: NCT06059989
Drug: Immunosuppressive Agents
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination group only
Trial: NCT06725355
Drug: IN-R00002
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single administration of IN-R00002 60mg
Trial: NCT06725355
Drug: IN-G00002
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single administration of IN-G00002 60mg
Trial: NCT06225882
Drug: Oxaluria evolution.
FDA approved: no
EMA approved: no
PMDA approved: no
Description: To collect real data from the specific French experience by collecting data from patients treated throughout the country and to monitor in particular the evolution of oxaluria before and after treatment.
Trial: NCT06726278
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: participants will receive a placebo treatment, consisting of an inert substance that has no active pharmacological effect. The placebo is administered in the same manner (vaginally) and at the same time point as Misoprostol, but without any therapeutic action. This group is used to control for potential psychological effects of the intervention, ensuring that any observed
Trial: NCT06725641
Drug: Test preparation：Methylcholine chloroacetate for inhalation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cholinergic agonists
Trial: NCT06725641
Drug: Reference preparation：Methylcholine chloroacetate for inhalation（Provocholine）
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cholinergic agonists
Trial: NCT06040944
Drug: antipsychotic drugs inducing hyperprolactinemia
FDA approved: no
EMA approved: no
PMDA approved: no
Description: not exposed
Trial: NCT04673578
Drug: Celecoxib
RxNorm normalized name: Celecoxib
DrugBank: Celecoxib (DB00482)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Selective COX-2 inhibitor; nonsteroidal anti-inflammatory drug (NSAID)
Trial: NCT06231979
Drug: Normal saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 ml normal saline 0.9% per side in erector spinae block
Trial: NCT06225999
Drug: LLV (levoisomer form of leucovorin)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LLV will be administered via intravenous (IV) infusion on days 1 and 15 of each 28-day cycle.
Trial: NCT06345833
Drug: 3% TXA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3% TXA on TXA-soaked pledgets applied for 10 minutes with saline as the control.
Trial: NCT06345833
Drug: 1% TXA with local plus 3% TXA-soaked pledgets
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1% TXA with local plus 3% TXA-soaked pledgets with saline as the control.
Trial: NCT06489860
Drug: HIV
RxNorm normalized name: HIV
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Directions: For adults and for Children 1-12 years old. Indication: Anti-AIDS Drug. Ingredient: Organic Rice 91% and Honey 9% Powder (whole) 1g. Mix one packet with 6.8 fl oz (200 ml) of hot water (220ºF/100ºC) about three minutes until dissolved. Participants: Use 4 to 5 packets, use one pack each time after two hours.~Humidification: \<5%. Dosage Strength: 1.0 G/ 1 Unit, use one pack of 1 g for each time. Use within two years from the manufacturing date.
Trial: NCT06489860
Drug: Neoplasms
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Directions: For adults and for Children 1-12 years old. Indication: Malignant Neoplasms . Ingredient: Rice 90% and Honey 10% Powder (whole) 1g. Mix one packet with 6.8 fl oz (200 ml) of hot water (220ºF/100ºC) about three minutes until dissolved. Participants: Use 4 to 5 packets, use one pack each time after two hours.~Humidification: \<5%. Dosage Strength: 1.0 G/ 1 Unit, use one pack of 1 g for each time. Use within two years from the manufacturing date.
Trial: NCT04898322
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT04983745
Drug: Combination drug
RxNorm normalized name: combination drugs used in erectile dysfunction
FDA approved: no
EMA approved: no
PMDA approved: no
Description: niraparib and dostarlimab combination
Trial: NCT05545072
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A placebo to match dupilumab will be administered subcutaneously every 2 weeks until the end of treatment (EOT) at Week 52. Participants will receive a total of 26 doses.
Trial: NCT05545072
Drug: Intranasal Corticosteroid Sprays (INCS)
RxNorm normalized name: influenza A virus (H1N1) antigen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: All participants will undergo standardized background therapy with intranasal corticosteroid sprays (INCS) per standard of care (SoC). This will be continued throughout the entire study. Participants either receive fluticasone propionate or mometasone furoate.
Trial: NCT06527781
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: intravenous injection
Trial: NCT06238154
Drug: Flurbiprofen
RxNorm normalized name: Flurbiprofen
DrugBank: Flurbiprofen (DB00712)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: The efficacy of two different forms and amounts of active ingredient (100mg tablet vs 25% oral spray) on postoperative pain of different flurbiprofen
Trial: NCT06252727
Drug: Aminolevulinic Acid
RxNorm normalized name: Aminolevulinic Acid
DrugBank: Aminolevulinic acid (DB00855)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given PO
Trial: NCT01579890
Drug: Diclofenac
RxNorm normalized name: Diclofenac
DrugBank: Diclofenac (DB00586)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: diclofenac topical lotion
Trial: NCT05236608
Drug: ADG106
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered as an intravenous infusion over 90 minutes.
Trial: NCT04078555
Drug: ENERGI-F703 GEL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The study medication will be applied twice daily until the end of 84 days or up to the visit confirmation of complete ulcer closure, whichever comes first.~The estimated amount of study medication applied to the ulcer area is 0.25 cm (about 0.11 g) in length per cm2 of ulcer size.
Trial: NCT04078555
Drug: ENERGI-F703 GEL matched vehicle
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The study medication will be applied twice daily until the end of 84 days or up to the visit confirmation of complete ulcer closure, whichever comes first.~The estimated amount of study medication applied to the ulcer area is 0.25 cm (about 0.11 g) in length per cm2 of ulcer size.
Trial: NCT05074394
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diluent solution
Trial: NCT05703204
Drug: QLF32101
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The dose is given weekly and observed for 28 days(DLT observation period).Single agent treatment.
Trial: NCT05104749
Drug: Homeopathic Medication
RxNorm normalized name: homeopathic medication
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Homeopathic medicines are prepared according to standardized methods as specified by the Homeopathic Pharmacopoeia of the United States (HPUS), which was mandated by Congress to regulate the manufacture of homeopathic medicines as part of the Food, Drug, and Cosmetics Act of 1939. All homeopathic medicines prescribed in this study must be found in the HPUS. For a complete list of homeopathic medicines, contact the researchers.
Trial: NCT05001750
Drug: long term prophylactic antibiotics (Nafcillin or Doxycycline)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: VRIs in patients who also receive a pre-procedural dose of antibiotics with continued dosing of antibiotics for the duration of the external ventricular drain IRB NUMBER: 2021-12680 IRB APPROVAL DATE: 06/14/2021 NOABX in EVD Study 3 (EVD).
Trial: NCT05649878
Drug: Evaluation of bioavailability of methylprednisolone succinate administered intravenously
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bioavailability of methylprednisolone in healthy subjects of both genders, when administered intravenously. The nominal doses were similar, volunteers were randomly assigned to receive a single dose of MEP by IV bolus of 1.5 mL. Venous blood samples were obtained via an indwelling catheter before administration and at 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 8, 12 and 24 h for DXM. Plasma was separated and frozen at -70 °C for further analysis.
Trial: NCT05649878
Drug: Evaluation of bioavailability of methylprednisolone succinate administered intranasally
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bioavailability of methylprednisolone in healthy subjects of both genders, when administered intranasally. Volunteers were randomly assigned to receive a single dose of MEP intranasally by using a Mucosal Atomization Device (MAD Nasal). allowing direct pharmacokinetic comparison without dose normalization. Venous blood samples were obtained via an indwelling catheter before administration and at 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 8, 12 and 24 h for DXM. Plasma was separated and frozen at -70 °C for further analysis.
Trial: NCT05309902
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Soticlestat placebo-matching tablet.
Trial: NCT05309902
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Moxifloxacin placebo-matching capsule.
Trial: NCT06227897
Drug: Aumolertinib
RxNorm normalized name: aumolertinib
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aumolertinib 110 mg per day orally for 3 years.
Trial: NCT05976802
Drug: Matching placebo rectal foam
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Twice a day for 2 weeks, then once a day for 4 weeks
Trial: NCT05565391
Drug: Standard of care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard of care
Trial: NCT06506292
Drug: XELOX
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: oxaliplatin: 130 mg/m2,iv,d1; capecitabine: 1000 mg/m2,po,pid,d1-d14
Trial: NCT04678830
Drug: Placebos
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebos
Trial: NCT04789915
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo add on to aripiprazole
Trial: NCT04994743
Drug: CORT113176
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CORT113176 lipid capsule formulation for oral administration
Trial: NCT04994743
Drug: Placebo matching CORT113176
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo matching CORT113176 lipid capsule formulation for oral administration
Trial: NCT04865419
Drug: AZD0466
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AZD0466 powder for concentrate for solution for infusion will be administered by IV infusion.
Trial: NCT05102266
Drug: BR1016D
FDA approved: no
EMA approved: no
PMDA approved: no
Description: All subjects who have been fasting for at least 10 hours prior to administration will take 1 tablet of study drug or comparator orally with 150 mL of water at room temperature at around 8 a.m. on the administration day of each period.
Trial: NCT05073718
Drug: Low-dose acetylsalicylic acid
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: In case of being positive for SARS-CoV-2 PCR or antigen test, she will be randomised 1:1 to receive daily LDASA (125 mg) or placebo, up to 36 weeks of pregnancy.
Trial: NCT05073718
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT06315400
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 capsule/day for 5 days
Trial: NCT04954040
Drug: Hydroxychloroquine Pill + Azithromycin Pill
RxNorm normalized name: hydroxychloroquine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hydroxychloroquine. 1st day 200mg 2-0-2; 2nd to 5th day 200mg 1-0-1 Azithromycin.~1st day 500m 0-1-0, 2nd to 5th day 250mg 0-1-0
Trial: NCT04954040
Drug: SOC
RxNorm normalized name: Isocet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acetaminophen or Metamizole. Antitussives if needed.
Trial: NCT06631976
Drug: 1ml of Depo-Medrol® injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1ml of methylprednisolone acetate (40mg/ml) injection into subacromial bursa.
Trial: NCT06631976
Drug: Tropocells® PRP injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tropocells® PRP injection. Patients will have an 11ml venous blood sample taken. After centrifugation, the obtained preparation will be administered to the patients intratendinously.
Trial: NCT06629051
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Looks the same as berberine
Trial: NCT04601467
Drug: AZD5718
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral dose of AZD5718 (tablet) once daily for 12 months
Trial: NCT04601467
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral dose of matching placebo (tablet) once daily for 12 months
Trial: NCT05230901
Drug: Spironolactone 25mg
RxNorm normalized name: SPIRONOLACTONE 25MG TAB
DrugBank: Spironolactone (DB00421)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Patients with CMR-derived ECV% levels ≥25.9% in Arm Spironolactone will receive spironolactone 25 mg/d in addition to standard of care medication .
Trial: NCT04731051
Drug: standard of care (SOC) for COVID-19
RxNorm normalized name: covid-19, protein subunit
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard of care (SOC) for COVID-19
Trial: NCT05796440
Drug: LUM-201
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered orally once daily
Trial: NCT05276817
Drug: HP
RxNorm normalized name: HPA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HP solution will be inserted to the bottom of the periodontal pocket using a disposable side port needle applicator. The solution will be in the pocket for 30 seconds, and then removed using sterile gauze and water spray.
Trial: NCT04709796
Drug: Conventional Transfer
RxNorm normalized name: SET,TRANSFER
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The control arm is the conventional embryo transfer without Embryo glue medium
Trial: NCT05077280
Drug: Immunotherapy
RxNorm normalized name: Dog immunotherapy extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Opdualag (nivolumab 480mg and relatlimab 160mg) will be given every 4 weeks for two years
Trial: NCT06310616
Drug: VH4524184
FDA approved: no
EMA approved: no
PMDA approved: no
Description: VH4524184 will be administered.
Trial: NCT05193604
Drug: TQB2858 injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TQB2858 injection is a programmed cell death 1 ligand 1 (PD-L1)/transforming growth factor-β bispecific antibody.
Trial: NCT04970654
Drug: Norditropin®
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Norditropin® (0.034 mg/kg/day) will be administered s.c. once daily by FlexPro® pen-injector. Norditropin® should be injected daily in the evening. The dose will be calculated based on the subject's current body weight.
Trial: NCT05721170
Drug: Beta blocker
RxNorm normalized name: Beta blocker
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Investigation on beta-blockers in TAVI and brief post-TAVI period.
Trial: NCT05289986
Drug: DELSTRIGO 100Mg-300Mg-300Mg Tablet
RxNorm normalized name: DELSTRIGO 100mg-300mg-300mg Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Delstrigo (300 mg of tenofovir disoproxil fumarate equivalent to 245 mg of tenofovir disoproxil, 300 mg of lamivudine and 100 mg of doravirine~- TDF/3TC/DOR)
Trial: NCT04246762
Drug: Caffeine
RxNorm normalized name: Caffeine
DrugBank: Caffeine (DB00201)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tablets, 100 mg, oral
Trial: NCT05826951
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT03692312
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching placebo formulation
Trial: NCT04713670
Drug: (E) BQ-V14
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: vonoprazan(vocinti)-based bismuth quadruple therapy for 14 days (BQ-V14)
Trial: NCT04713670
Drug: (G) BQ-L14
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: lansoprazole(takepron)-based bismuth quadruple therapy for 14 days (BQ-L14)
Trial: NCT05921435
Drug: CKD-341, D958
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A single dose of 1tablet under fasting condition
Trial: NCT05315024
Drug: Fluarix Tetra
RxNorm normalized name: Fluarix 2024-2025
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluarix Tetra
Trial: NCT04964479
Drug: TQB2450 injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1200mg injection once every 3 week
Trial: NCT04964479
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo capsule once daily
Trial: NCT05561023
Drug: Hawthorn red pigment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: For patients with refractory cancer pain who meet the enrollment conditions, on the basis of the clinician's normal adjustment of the analgesic regimen (the initial adjustment is the first day), the dose ramp up study of Hawthorn red pigment was started on the third day. The Hawthorn red dose group includes 10 tablets → 15 tablets → 20 tablets / time, orally, twice a day.~3 + 3 dose escalation scheme
Trial: NCT05677282
Drug: Azithromycin 500 MG
RxNorm normalized name: azithromycin 500 MG
DrugBank: Azithromycin (DB00207)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Azithromycin 500 mg as a single dose administered orally.
Trial: NCT03137966
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo will be applied locally as a gel (3 times a week) for a period of maximum three months or until intact skin.
Trial: NCT05659927
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single subcutaneous injection. Subjects with a dose of less than or equal to 2 ml were given one injection, and subjects with a dose of more than 2 ml were given two injections. A group 0.5 ml, B group 1 ml, C group 2 ml, D group 4 ml.
Trial: NCT00449124
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Injections of 0.5 mL of normal saline solution (0.9% NaCl).
Trial: NCT06555146
Drug: Placebo, Saline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 subcutaneous injection on baseline day
Trial: NCT05532358
Drug: anle138b (TEV-56286)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anle138b (TEV-56286) as perpetrator
Trial: NCT05072938
Drug: Mucotra SR Tablet 150mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rebamipide/Nizatidine Combination Therapy
Trial: NCT06375824
Drug: Bufei Recipe placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The placebo was prepared using 5% of the drug, with color, odor, taste, appearance, and weight similar to the experimental group drug, and packaging consistent with the experimental group drug.
Trial: NCT05533164
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo in 250ml NaCl 0.9% intravenously